Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023. In the quarter to September 2025, revenue fell 36.4%, EPS grew 78.3% and free cash flow fell 41.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow LIPO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|
Cash and Short Term Investments |
0.03 | 0.61 | 1.71 | 5.12 | 3.29 | 2.18 |
Receivables |
0.08 | 0.07 | — | 0.11 | 0.03 | 0.08 |
Other current assets |
0.01 | — | — | — | — | — |
Total current assets |
0.12 | 0.70 | 1.81 | 5.80 | 3.43 | 2.62 |
Property, Plant, Equpment (Net) |
— | 0.26 | 0.20 | 0.15 | 0.01 | 0.01 |
Total non-current assets |
— | 0.26 | 0.20 | 0.15 | 0.15 | 0.06 |
Total Assets |
0.12 | 0.96 | 2.01 | 5.95 | 3.58 | 2.67 |
Notes Payable |
— | — | — | 0.03 | — | — |
Accounts Payable |
0.05 | 0.02 | 0.05 | 0.38 | 0.14 | 0.39 |
Accrued Expenses |
— | — | 0.15 | 0.39 | 0.08 | 0.24 |
Current Part of Debt |
0.05 | 0.08 | 0.03 | 0.25 | — | — |
Other current liabilities |
0.07 | 0.05 | 0.08 | 0.07 | 0.08 | 0.08 |
Total current liabilities |
0.17 | 0.21 | 0.34 | 1.18 | 0.39 | 0.75 |
Long Term Debt (Total) |
0.05 | 0.05 | 0.05 | — | — | — |
Non-current Liabilities (Other) |
0.02 | 0.03 | 0.03 | — | — | — |
Total non-current liabilities |
— | 0.28 | 0.25 | 0.10 | 0.05 | — |
Total liabilities |
0.24 | 0.49 | 0.59 | 1.27 | 0.43 | 0.75 |
Additional Paid In Capital |
— | 1.70 | 4.53 | 10.38 | 13.47 | 17.26 |
Preferred Stock (Total) |
— | 0.00 | 0.00 | — | — | 0.00 |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
— | (1.24) | (3.11) | (5.70) | (10.32) | (15.34) |
Common Equity (Total) |
(0.12) | 0.46 | 1.42 | 4.68 | 3.14 | 1.92 |
Shareholders Equity (Total) |
(0.12) | 0.46 | 1.42 | 4.68 | 3.14 | 1.92 |
Shareholders Equity and Liabilities (Total) |
— | 0.96 | 2.01 | 5.95 | 3.58 | 2.67 |
Shares (Common) |
— | 0.72 | 0.48 | 0.72 | 0.76 | 1.21 |
Shares (Preferred) |
— | 0.20 | 0.20 | — | — | 0.33 |
Shareholders Equity (Tangible) |
— | 0.46 | 1.42 | 4.68 | 3.14 | 1.92 |
Net Debt |
0.07 | (0.48) | (1.64) | (4.87) | (3.29) | (2.18) |
Total Debt |
0.10 | 0.13 | 0.08 | 0.25 | — | — |